Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.
- Associate Professor, Infectious Diseases, Medicine, Boston University School of Medicine
- New York University School of Medicine, MD
- Harvard School of Public Health, MPH
- Yale University, BA
- Published on 3/17/2020
Assoumou SA, Tasillo A, Vellozzi C, Eftekhari Yazdi G, Wang J, Nolen S, Hagan L, Thompson W, Randall LM, Strick L, Salomon JA, Linas BP. Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons. Clin Infect Dis. 2020 Mar 17; 70(7):1388-1396. PMID: 31095676.
- Published on 3/17/2020
Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, Akiyama MJ, Norton BL, Litwin AH, Linas BP. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clin Infect Dis. 2020 Mar 17; 70(7):1397-1405. PMID: 31095683.
- Published on 3/4/2020
Assoumou SA, Wang J, Nolen S, Eftekhari Yazdi G, Mayer KH, Puro J, Salomon JA, Linas BP. HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic. J Gen Intern Med. 2020 Mar 04. PMID: 32133577.
- Published on 2/1/2020
Ghany MG, Morgan TR. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020 Feb; 71(2):686-721. PMID: 31816111.
- Published on 1/30/2020
Linas BP. Time for a New Approach to Guidance for HIV and HCV Testing Among Persons Who Inject Drugs. J Infect Dis. 2020 Jan 30. PMID: 32002538.
- Published on 1/20/2020
Moloney PB, Hutchinson S, Heskin J, Mulcahy F, Langan Y, Conlon NP, Linas BP, Takahashi C, Cervantes-Arslanian AM. Possible N-methyl-D-aspartate receptor antibody-mediated encephalitis in the setting of HIV cerebrospinal fluid escape. J Neurol. 2020 Jan 20. PMID: 31960135.
- Published on 12/10/2019
Epstein RL, Wang J, Hagan L, Mayer KH, Puro J, Linas BP, Assoumou SA. Hepatitis C Virus Antibody Testing Among 13- to 21-Year-Olds in a Large Sample of US Federally Qualified Health Centers. JAMA. 2019 12 10; 322(22):2245-2248. PMID: 31821424.
- Published on 11/15/2019
Bellerose M, Zhu L, Hagan LM, Thompson WW, Randall LM, Malyuta Y, Salomon JA, Linas BP. A review of network simulation models of hepatitis C virus and HIV among people who inject drugs. Int J Drug Policy. 2019 Nov 15; 102580. PMID: 31740175.
- Published on 10/10/2019
Kimmel SD, Walley AY, Linas BP, Kalesan B, Awtry E, Dobrilovic N, White L, LaRochelle M. Effect of Publicly Reported Aortic Valve Surgery Outcomes on Valve Surgery in Injection Drug- and Non-Injection Drug-Associated Endocarditis. Clin Infect Dis. 2019 Oct 10. PMID: 31598642.
- Published on 7/3/2019
Linas BP. The 340B System-A Paradox Revealed. JAMA Netw Open. 2019 Jul 03; 2(7):e196537. PMID: 31276173.
View 81 more publications: View full profile at BUMC